The Role of a Mycobacterium Growth Inhibition Assay to Quantify Host Immune Control of M. Tuberculosis

Launched by LINKOEPING UNIVERSITY · Aug 28, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how the immune system in our blood can control a bacteria called M. tuberculosis, which causes tuberculosis (TB). Researchers want to find out if the ability of blood cells from healthy people to fight off this bacteria is different compared to people who have been exposed to TB but don’t have active disease (latent TB) versus those who do have active TB. Essentially, they are looking at how well our body can keep this bacteria from growing in our blood.

To participate, you need to be either a healthy blood donor or someone who is about to receive a vaccine. However, if you have certain conditions like HIV, chronic liver or kidney disease, or if you are on treatments that weaken your immune system, you won’t be eligible. Participants in the study can expect to provide blood samples, which will help researchers learn more about how our immune system works against TB. This study is important because it could help improve ways to detect and treat TB in the future.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria: Healthy blood donors or subjects who will get vaccinated.
• • Exclusion Criteria:Known HIV infection, not Swedish citizen, chronic liver och kidney disease,immunosuppression from treatment or disease.